BROKERS CHOICE: NTPC, POWERGRID, ASTRAL, HDFCBANK, PIRAMALPHARMA, AXISBANK

AHMEDABAD, 25 SEPTEMBER: અગ્રણી બ્રોકરેજ હાઉસ તથા ફંડ હાઉસ તરફથી પસંદગીના સ્ટોક્સમાં ખરીદી\ વેચાણ\ હોલ્ડ કરવા માટે ભલામણ કરવામાં આવી છે. તે રોકાણકારોના અભ્યાસ માટે અત્રે રજૂ કરીએ છીએ.

Jefferies on Piramal Pharma: Maintain Buy on Company, raise target price at Rs 260/Sh (Positive)

Macquarie on BEL: Maintain Outperform on Company, target price at Rs 350/Sh (Positive)

GS on NTPC: Maintain Buy on Company, target price at Rs 430/Sh (Positive)

GS on Power Grid: Maintain Buy on Company, target price at Rs 370/Sh (Positive)

CLSA on Astral: Upgrade to Hold on Company, target price at Rs 2025/Sh (Positive)

HSBC on HDFC Bank: Maintain Buy on Bank, target price at Rs 2010/Sh (Positive)

Bernstein on Financials: Top picks in financials include HDFC Bank, Axis Bank and Muthoot Finance amongst NBFCs. (Positive)

BofA India Strategy: Policy shift = pivot for sector rotation. Favors Staples, Financials, Healthcare, Telecom and Autos (Positive)

Goldman Sachs India Strategy: India is likely to be among the fastest growing economies in the medium-term (Positive)

Antique on Piramal Pharma: Enhanced productivity and cost optimization initiatives are likely to drive its EBITDA margin expansion to ~25% from the current ~15% (Positive)

Jefferies India strategy: Valuation is a key concern for FPIs but willingness to explore new ideas from industrial and capex segment was visible (Neutral)

UBS on Dabur: Downgrade to Neutral on Company, raise target price at Rs 700/Sh (Neutral)

MS on MCX: Maintain Underweight on Company, target price at Rs 2950/Sh (Neutral)

(Disclaimer: The information provided here is investment advice only. Investing in the markets is subject to risks and please consult your advisor before investing.)

(સ્પષ્ટતા: અત્રેથી આપવામાં આવતી તમામ પ્રકારની માહિતી કોઇપણ પ્રકારે રોકાણ/ ટ્રેડીંગ માટેની સલાહ નથી. બજારોમાં રોકાણ જોખમોને આધીન છે અને રોકાણ કરતા પહેલા કૃપા કરીને તમારા સલાહકારની સલાહ લો.)